You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

Claims for Patent: 7,060,250


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,060,250
Title:Diagnostic imaging contrast agents with extended blood retention
Abstract:The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.
Inventor(s): McMurry; Thomas J. (Winchester, MA), Sijiki; Hironao (Gifu, JP), Scott; Daniel M. (Acton, MA), Lauffer; Randall B. (BrookIine, MA)
Assignee: Epix Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:10/755,506
Patent Claims: 1. A pharmaceutically acceptable salt of a diagnostic imaging contrast agent having a structure selected from the group consisting of: ##STR00027## wherein Ph=phenyl, ##STR00028## wherein Ph=phenyl, ##STR00029## wherein Ph=phenyl, ##STR00030## wherein Me=methyl, ##STR00031## wherein Ph=phenyl, and ##STR00032## wherein Ph=phenyl.

2. The pharmaceutically acceptable salt of claim 1, wherein the salt is selected from the group consisting of calcium, sodium, N-methyl-glucamine, and mixtures thereof.

3. The pharmaceutically acceptable salt of claim 1, wherein the diagnostic imaging contrast agent has the structure: ##STR00033## wherein Ph is phenyl, and wherein the salt is sodium.

4. The pharmaceutically acceptable salt of claim 1, wherein the diagnostic imaging contrast agent has the structure: ##STR00034## wherein Ph is phenyl, and wherein the salt is N-methyl-glucamine.

5. The phannaceutically acceptable salt of claim 1, wherein the diagnostic imaging contrast agent has the structure: ##STR00035## wherein Ph is phenyl, and wherein the salt is a mixture of sodium and N-methyl-glucamine.

6. A chelating ligand having the structure: ##STR00036##

7. A chelating ligand having the structure: ##STR00037##

8. A chelating ligand having the structure: ##STR00038##

9. A chelating ligand having the structure: ##STR00039##

10. A chelating ligand having the structure: ##STR00040##

11. A chelating ligand having the structure: ##STR00041##

12. A chelating ligand having the structure: ##STR00042##

13. A chelating ligand having the structure: ##STR00043##

14. A pharmaceutically acceptable salt of a chelating ligand according to any of claims 6 13.

15. The pharmaceutically acceptable salt of claim 14, wherein the salt is selected from the group consisting of calcium, sodium, N-methyl-glucamine, and mixtures thereof.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.